Exploration of Immune Response to Pneumococcal Conjugate Vaccine (PCV13) Administered Before and Early After Autologous Peripheral Stem Cell Transplant (Auto-PSCT) in Patients With Multiple Myeloma
This is a pilot study to determine the safety of PCV13 administered to patients with myeloma
before and at +7 and +21 after autologous hematopoietic stem cell transplant; and,to
quantify the immune response induced by PCV13 vaccination in patients with myeloma when
administered before and early after autologous PSCT.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
Efficacy based on immunologic response pre/post-vaccination.
Frederick L Locke, MD
H. Lee Moffitt Cancer Center and Research Institute
United States: Food and Drug Administration
MCC - 16727
|H.Lee Moffitt Cancer Center & Research Institute||Tampa, Florida 33612|